EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSECRG00000021519
Gene Symbol: CACNA1D
3 Cross references
285 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSECRG00000009592
Gene Symbol: CACNA1F
3 Cross references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSECRG00000023055
Gene Symbol: CACNA1G
2 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSECRG00000009453
Gene Symbol: CACNA1H
3 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSECRG00000015788
Gene Symbol: CACNA1I
2 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSECRG00000003689
Gene Symbol: CACNA1S
3 Cross references
268 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSECRG00000003588
Gene Symbol: CNR1
3 Cross references
207 Possible Orthologues:

Cannabinoid Receptor Type 1a-Like

Ensembl ID : ENSECRG00000016390
Gene Symbol: LOC114664854
3 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSECRG00000021340
Gene Symbol: CA12
3 Cross references
215 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSECRG00000014210
Gene Symbol: LOC114655765
3 Cross references
272 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSECRG00000008008
Gene Symbol: LOC114655622
3 Cross references
201 Possible Orthologues:

Carbonic Anhydrase 5a

Ensembl ID : ENSECRG00000007044
Gene Symbol: CA5A
3 Cross references
231 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).